Evidence map›Paper›PMID 38359298›Full record

ArticleJornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia2024

Role of the IL8 rs4073 polymorphism in central nervous system toxicity in patients receiving multidrug-resistant tuberculosis treatment.

Ibrahim Mohammed Badamasi, Muktar Muhammad, Aishat Ahmad Umar, Umm-Ayman Misbahu Madugu, Muktar Ahmed Gadanya, Isa Abubakar Aliyu, Imam Malik Kabir, Ibrahim Aliyu Umar, Ochigbo Johnson, Johnson Stanslas

Open access · diamondAbstract read
In one paragraph

Article in Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Ibrahim Mohammed Badamasi. Pharmacogenomic Unit, Department of Human Anatomy, Faculty of Basic Medical Sciences - FBMS - College of Medicine, Bayero University, Kano, Kano, Nigeria.ORCID 0000-0002-6747-4468
Muktar Muhammad. Pharmacogenomic Unit, Department of Human Anatomy, Faculty of Basic Medical Sciences - FBMS - College of Medicine, Bayero University, Kano, Kano, Nigeria.ORCID 0000-0002-8632-7762
Aishat Ahmad Umar. Pharmacogenomic Unit, Department of Human Anatomy, Faculty of Basic Medical Sciences - FBMS - College of Medicine, Bayero University, Kano, Kano, Nigeria.ORCID 0009-0006-6736-1267
Umm-Ayman Misbahu Madugu. Pharmacogenomic Unit, Department of Human Anatomy, Faculty of Basic Medical Sciences - FBMS - College of Medicine, Bayero University, Kano, Kano, Nigeria.ORCID 0009-0009-6450-3241
Muktar Ahmed Gadanya. Department of Community Medicine, Faculty of Clinical Sciences, Bayero University, Kano, Kano, Nigeria.ORCID 0000-0003-0061-5219
Isa Abubakar Aliyu. Department of Medical Laboratory Science, Faculty of Allied Health Sciences - FAHS - Bayero University, Kano, Kano, Nigeria.ORCID 0000-0002-1484-2837
Imam Malik Kabir. Department of Medical Laboratory Science, Faculty of Allied Health Sciences - FAHS - Bayero University, Kano, Kano, Nigeria.ORCID 0000-0002-2645-7282
Ibrahim Aliyu Umar. Kano State TB and Leprosy Control Program, Kano State Ministry of Health, Kano, Nigeria.ORCID 0000-0002-8128-3422
Ochigbo Johnson. Kano State Infectious Disease Hospital, Kano State Ministry of Health, Kano, Nigeria.ORCID 0009-0004-6842-4616
Johnson Stanslas. Pharmacotherapeutics Lab, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia.ORCID 0000-0002-6938-954X
Bayero University Kano · NGAminu Kano Teaching Hospital · NGUniversiti Putra Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the role of the IL8 rs4073 polymorphism in predicting the risk of central nervous system (CNS) toxicity in patients receiving standard pharmacological treatment for multidrug-resistant tuberculosis (MDR-TB).

methodsA cohort of 85 consenting MDR-TB patients receiving treatment with second-line antituberculosis drugs had their blood samples amplified for the IL8 (rs4073) gene and genotyped. All patients were clinically screened for evidence of treatment toxicity and categorized accordingly. Crude and adjusted associations were assessed.

resultsThe chief complaints fell into the following categories: CNS toxicity; gastrointestinal toxicity; skin toxicity; and eye and ear toxicities. Symptoms of gastrointestinal toxicity were reported by 59% of the patients, and symptoms of CNS toxicity were reported by 42.7%. With regard to the genotypes of IL8 (rs4073), the following were identified: AA, in 64 of the study participants; AT, in 7; and TT, in 11. A significant association was found between the dominant model of inheritance and CNS toxicity for the crude model (p = 0.024; OR = 3.57; 95% CI, 1.18-10.76) and the adjusted model (p = 0.031; OR = 3.92; 95% CI, 1.13-13.58). The AT+TT genotype of IL8 (rs4073) showed a 3.92 times increased risk of CNS toxicity when compared with the AA genotype.

conclusionsThe AT+TT genotype has a tendency to be associated with an increased risk of adverse clinical features during MDR-TB treatment.

Indexed as

Interleukin-8Tuberculosis, Multidrug-ResistantAntitubercular AgentsGenotypeHumansAntitubercular AgentsInterleukin-8

Identifiers

PMID38359298
PMCPMC11095930
OpenAlexW4390910745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.